- Home
- TSHA vs LSAK Comparison
TSHA vs LSAK Comparison
Compare TSHA & LSAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- LSAK
- Stock Information
- Founded
- TSHA 2019
- LSAK 1997
- Country
- TSHA United States
- LSAK South Africa
- Employees
- TSHA N/A
- LSAK N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- LSAK Investment Bankers/Brokers/Service
- Sector
- TSHA Health Care
- LSAK Finance
- Exchange
- TSHA Nasdaq
- LSAK Nasdaq
- Market Cap
- TSHA 397.8M
- LSAK 408.0M
- IPO Year
- TSHA 2020
- LSAK N/A
- Fundamental
- Price
- TSHA $2.71
- LSAK $4.24
- Analyst Decision
- TSHA Strong Buy
- LSAK
- Analyst Count
- TSHA 7
- LSAK 0
- Target Price
- TSHA $7.00
- LSAK N/A
- AVG Volume (30 Days)
- TSHA 5.2M
- LSAK 23.5K
- Earning Date
- TSHA 05-15-2025
- LSAK 05-07-2025
- Dividend Yield
- TSHA N/A
- LSAK N/A
- EPS Growth
- TSHA N/A
- LSAK N/A
- EPS
- TSHA N/A
- LSAK N/A
- Revenue
- TSHA $7,224,000.00
- LSAK $574,080,000.00
- Revenue This Year
- TSHA N/A
- LSAK $0.04
- Revenue Next Year
- TSHA N/A
- LSAK $1.74
- P/E Ratio
- TSHA N/A
- LSAK N/A
- Revenue Growth
- TSHA N/A
- LSAK 4.13
- 52 Week Low
- TSHA $1.05
- LSAK $3.39
- 52 Week High
- TSHA $4.32
- LSAK $5.60
- Technical
- Relative Strength Index (RSI)
- TSHA 60.38
- LSAK 47.53
- Support Level
- TSHA $2.44
- LSAK $4.05
- Resistance Level
- TSHA $2.95
- LSAK $4.34
- Average True Range (ATR)
- TSHA 0.25
- LSAK 0.21
- MACD
- TSHA -0.02
- LSAK 0.01
- Stochastic Oscillator
- TSHA 51.60
- LSAK 50.00
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About LSAK Lesaka Technologies Inc.
Lesaka Technologies Inc provides payment solutions, transaction processing solutions, and financial technologies. The company operates two reportable segments: Merchant and Consumer. The company operates mainly within South Africa. The Merchant segment that derives majority revenue includes activities related to the provision of goods and services provided to corporate and other juristic entities. It earns fees from processing activities performed for its customers and revenue generated from the distribution of prepaid airtime. The Consumer segment includes activities related to the provision of financial services to customers, including bank accounts, loans, and insurance products. The firm charges monthly administration fees for all bank accounts.